By Dennis Ford, Founder & CEO, LSN
The challenge with life science partnering and investor conferences is that it is extremely difficult to recruit investors and partners. At LSN, we often say that we are “in the middle of the middle of the middle”. We have 8 researchers who have been in dialogue with the global early stage investor community for 4 years as a result of curating the LSN Investor Platform. Additionally, LSN has 8 business development staff who have been driving relationships with scientist entrepreneurs, Pharma players and service providers. These two outreach teams have created a loosely affiliated global network of the key buyers and sellers. LSN founded the Redefining Early Stage Investments conference (RESI) because we believed we could bring a greater quantity of early stage investors than we’d seen at other events. At many events, it’s easier to meet later stage players: LSN staff attended events billed as partnering conferences that produced lots of phase III partners but not a lot for preclinical, phase I and phase II. Early stage is where LSN found its niche, and that’s why RESI @ JPM attracted 350 investor and partner registrations out of a total of almost 800 registrants. LSN knows what it takes to bring this many early stage life science players under one roof.
LSN has broken the code of delivering investors to our early stage investor conferences because we pour a huge amount of human resources into recruiting investors to RESI. LSN Research staff focus their efforts into personally recruiting investors attendees to each event. LSN can do this because as a company we interact with all the right players as part of our everyday working environment. The 16 early stage investor panels are a core part of every RESI, and serve as proof of what we can deliver. In the panel sessions, investors explain to the audience of fundraising CEOs how their investor silo works, and cover the do’s and don’ts related to how they find, vet and engage in dialogue with investment candidates. The panels provide information and education to RESI’s audience. LSN’s unique position in the early stage life science world gives us access to high level speakers with deep expertise to share.
Take a look at the RESI@TMCx agenda for an overview of the next event at the Texas Medical Center accelerator, April 11, in Houston Texas.
Of course, investors and strategic players will only attend a partnering event if they’re confident that they’ll meet high quality life science startups. So on the other side of the table, the RESI Innovation Challenge provides investors with access to exciting breakthrough technologies. LSN invites fundraising CEOs and scientist-entrepreneurs to submit their technologies to the Innovation Challenge. Typically, over 100 companies apply for 30 spots; LSN’s scientific review board “stack ranks” the applicants using a proprietary algorithm that LSN has developed which determines how investable a company is from the science, market, team, data and competitive landscape.
Bringing the best of the early stage investor world and the best of the life science startup world together takes an intensive effort, but that’s what makes RESI such a powerful venue for dialogue. If you’d like to join us for RESI@TMCx on April 11th, you can register online now.